Parkinson’s disease affects the central nervous system leading to a progressive and chronic movement disorder, where the affected individual slowly develops difficulty in control of movements over a period of 10 to 20 years usually with a constellation of symptoms due to…
The exact cause of such effects is not known, although aggressive research in this area is underway. Irrespective of the cause, a patient with full-blown Parkinson’s disease will have four cardinal symptoms, tremor at rest, bradykinesia, rigidity, and difficulties with balance. Such patients due to difficulty in movement control are virtually rendered nonfunctional, and the quality of their life is severely affected (1).
From the market point of view, thus there is huge untapped potential in the Parkinsons disease therapy market. The exact cause of the disease is not known, but a considerable number of individuals suffer from this problem. The medical therapy assumes a central role in the management plan, and therefore a variety of medications are available for symptomatic treatment. Despite new research to discover newer drugs, there is no medication as yet which has shown promise in arresting the pathological process of the Parkinsons disease. Therefore, this existing gap can create opportunities newer modalities of therapies, therapeutic agents, or curative agents (1).
The Worldwide market of Parkinson’s disease is huge, since it is a common neurological disease with a disease burden of 4.1m affected individual. It is expected that its prevalence will rise in the coming years with increased clinical interventions in different forms. Current treatments or therapeutic choices are unsatisfactory making the unmet needs of this market a huge one, creating significant market opportunity. Although the market is global, in developed world, almost all counties constitute the major markets of such drugs. These countries are USA, Japan, France, Italy, Germany, Spain, and the UK. Compared to last evaluation of 2006 the market has been predicted to grow beyond $4.6bn from its base of $2.2bn, which interestingly was 11% larger than its base of 2005. The market is expected to increase in an exponential rate due to the fact that ...
Cite this document
(“Executive Summary Memo for Market Analysis of Parkinson's Disease Research Paper”, n.d.)
Retrieved from https://studentshare.net/miscellaneous/397921-executive-summary-memo-for-market-analysis-of-parkinsons-disease
(Executive Summary Memo for Market Analysis of Parkinson'S Disease Research Paper)
“Executive Summary Memo for Market Analysis of Parkinson'S Disease Research Paper”, n.d. https://studentshare.net/miscellaneous/397921-executive-summary-memo-for-market-analysis-of-parkinsons-disease.
The earliest known record of the study of Parkinson’s Disease is mentioned in James Parkinson’s “Essay on the Shaking Palsy”. The article describes the most common features of the disease which remain as the standard by which other types of parkinsonism are compared.
The etiology of the disease has been discussed in relation to both the genetic and environmental factors. Important genes causing inherited Parkinson’s disease are LRRK2, PINK1, Parkin gene, SNCA and DJ-1. The mutations can result either in dominant or recessive Parkinson’s disease.
Some chronic disease may result in immediate danger for an individual’s life, though commonly, chronic diseases are persistent and are not necessarily life threatening. Examples of chronic diseases include cancer, arthritis, stroke and Parkinson’s disease among other numerous examples.
Adopting a well stipulated indicator for measuring the performance before and after receiving physical therapy by the studied patients had been a significant criterion for selecting studies for this literature analysis. Other criteria for selecting theses particular studies include technical and convenience related considerations.
The etiology of the disease has been discussed in relation to both the genetic and environmental factors. Important genes causing inherited Parkinson’s disease are LRRK2, PINK1, Parkin gene, SNCA and DJ-1. The
Treatment during the early stages of the disease has progressed, and proof indicates that dopamine agonist monotherapy may put a stop to the change in response to the progression of the disease. Treatment during the further stages of the disease concentrates
One pathognomic feature of the remaining neurons in patients suffering from Parkinson’s disease is that they contain Lewy bodies. These are protein whose main structural component is alpha synuclein. At the early stages of the disease, the patients remain
et al., 2007).
Olympia Bakery is committed to be the best alternative dessert producer and supplier in the city. It will become a favorite spot for all our esteemed customers residing within and out of the in the city.
2 Pages(500 words)Assignment
GOT A TRICKY QUESTION? RECEIVE AN ANSWER FROM STUDENTS LIKE YOU!
Let us find you another Research Paper on topic Executive Summary Memo for Market Analysis of Parkinson's Disease for FREE!